183 related articles for article (PubMed ID: 29185289)
41. Severe hypocalcemia after denosumab in a patient with acquired Fanconi syndrome.
Shafqat H; Alquadan KF; Olszewski AJ
Osteoporos Int; 2014 Mar; 25(3):1187-90. PubMed ID: 24158473
[TBL] [Abstract][Full Text] [Related]
42. Extreme hypocalcaemia and hyperparathyroidism following denosumab. Is this drug safe in chronic kidney disease?
Sirvent AE; Enríquez R; Sánchez M; González C; Millán I; Amorós F
Nefrologia; 2014; 34(4):542-4. PubMed ID: 25036077
[No Abstract] [Full Text] [Related]
43. Safety and efficacy of denosumab in osteoporotic hemodialysed patients.
Festuccia F; Jafari MT; Moioli A; Fofi C; Barberi S; Amendola S; Sciacchitano S; Punzo G; Menè P
J Nephrol; 2017 Apr; 30(2):271-279. PubMed ID: 27394428
[TBL] [Abstract][Full Text] [Related]
44. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
[TBL] [Abstract][Full Text] [Related]
45. Bad Breaks.
Yalla N
Clin Chem; 2018 Jan; 64(1):47-50. PubMed ID: 29295835
[No Abstract] [Full Text] [Related]
46. Randomized controlled trial of alfacalcidol supplementation for the reduction of hypocalcemia after total thyroidectomy.
Genser L; Trésallet C; Godiris-Petit G; Li Sun Fui S; Salepcioglu H; Royer C; Menegaux F
Am J Surg; 2014 Jan; 207(1):39-45. PubMed ID: 24119718
[TBL] [Abstract][Full Text] [Related]
47. Management of Osteoporosis in Chronic Kidney Disease.
Nitta K; Yajima A; Tsuchiya K
Intern Med; 2017 Dec; 56(24):3271-3276. PubMed ID: 29021477
[TBL] [Abstract][Full Text] [Related]
48. [Clinical approach to patients with hypocalcemia].
Takeuchi Y
Clin Calcium; 2007 Aug; 17(8):1169-74. PubMed ID: 17660611
[TBL] [Abstract][Full Text] [Related]
49. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
Fahrleitner-Pammer A; Papaioannou N; Gielen E; Feudjo Tepie M; Toffis C; Frieling I; Geusens P; Makras P; Boschitsch E; Callens J; Anastasilakis AD; Niedhart C; Resch H; Kalouche-Khalil L; Hadji P
Arch Osteoporos; 2017 Dec; 12(1):58. PubMed ID: 28643265
[TBL] [Abstract][Full Text] [Related]
50. Denosumab: an antifracture therapy for postmenopausal women with osteoporosis.
Jiang X; Schnatz PF
Menopause; 2013 Feb; 20(2):117-9. PubMed ID: 23299707
[No Abstract] [Full Text] [Related]
51. High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis.
Ishikawa K; Nagai T; Tsuchiya K; Oshita Y; Kuroda T; Ito H; Tani S; Dodo Y; Toyone T; Inagaki K
Clin Interv Aging; 2018; 13():1929-1934. PubMed ID: 30349211
[TBL] [Abstract][Full Text] [Related]
52. Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis.
Yasuda Y; Iwama S; Arima H
Endocr J; 2019 Mar; 66(3):271-275. PubMed ID: 30713246
[TBL] [Abstract][Full Text] [Related]
53. Denosumab, osteoporosis, and prevention of fractures.
Kiechl S; Willeit J; Schett G
N Engl J Med; 2009 Nov; 361(22):2188-9; author reply 2190-1. PubMed ID: 19940304
[No Abstract] [Full Text] [Related]
54. Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency.
Ralston SH; Binkley N; Boonen S; Kiel DP; Reginster JY; Roux C; Chen L; Rosenberg E; Santora A;
Calcif Tissue Int; 2011 Jun; 88(6):485-94. PubMed ID: 21479913
[TBL] [Abstract][Full Text] [Related]
55. Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis.
Yerram P; Kansagra S; Abdelghany O
J Oncol Pharm Pract; 2017 Apr; 23(3):179-184. PubMed ID: 26830549
[TBL] [Abstract][Full Text] [Related]
56. Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.
Iizumi S; Shimoi T; Nishikawa T; Kitano A; Sasada S; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
Intern Med; 2017 Nov; 56(21):2879-2882. PubMed ID: 28943574
[TBL] [Abstract][Full Text] [Related]
57. Denosumab (Prolia): A new option in the treatment of osteoporosis.
Belavic JM
Nurse Pract; 2011 Jan; 36(1):11-2. PubMed ID: 21173630
[No Abstract] [Full Text] [Related]
58. Severe hypocalcaemia and hypophosphataemia following intravenous iron and denosumab: a novel drug interaction.
Smyth B; Ong S
Intern Med J; 2016 Mar; 46(3):360-3. PubMed ID: 26968599
[TBL] [Abstract][Full Text] [Related]
59. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
60. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
